title: Her2, EGFR and TOPIIA gene amplification and protein expression in synovial sarcoma before and after combined treatment.
abstract: Synovial sarcoma (SyS) occurs mostly in young adults and is characterized by an aggressive course. Combined treatment including chemotherapy, radiotherapy and surgical excision of the tumour is still not satisfactory, with mean 5-year survival of 30-50%. New targeted treatment options have appeared recently, e.g. HER2 and EGFR antagonists. Initial studies have revealed immunohistochemical overexpression of the EGFR in SyS; therefore trials with EGFR antagonist therapy have commenced. The aim of our study was to evaluate the status of HER2, EGFR and TOPIIA in SyS before and after combined therapy. Immunohistochemistry and FISH tests were performed. Significant discrepancies between protein expression and gene status were found. The authors discuss the potential reasons for that phenomenon.
authors: Department of Pathology, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw.
authors: Konrad
authors: K
authors: Ptaszyński
authors: Anna
authors: A
authors: Szumera-Ciećkiewicz
authors: Klara
authors: K
authors: Zakrzewska
authors: Tomasz
authors: T
authors: Tuziak
authors: Anna
authors: A
authors: Mrozkowiak
authors: Piotr
authors: P
authors: Rutkowski
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004250:DNA Topoisomerases, Type II / Q000235:genetics / Q000378:metabolism*; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D066246:ErbB Receptors / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005784:Gene Amplification; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011878:Radiotherapy; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000378:metabolism*; D013584:Sarcoma, Synovial / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000235:genetics / Q000378:metabolism* / Q000628:therapy*; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D004250:DNA Topoisomerases, Type II; D004268:DNA-Binding Proteins; D066246:ErbB Receptors; D007069:Ifosfamide; D018719:Erb-b2 Receptor Tyrosine Kinases; C512478:EGFR protein, human; C508053:ERBB2 protein, human